Alain P. Algazi

MD

Medical oncologist
Immunologist, father and rather slow endurance athlete

Dr. Alain Algazi is a specialist in medical treatment – such as chemotherapy and immunotherapy – for patients with head and neck cancers, including head and neck squamous cell carcinoma, thyroid cancers and salivary gland cancers. He leads UCSF's program in medical therapy for head and neck cancers, and chairs the head and neck cancer research committee.

In research, Algazi conducts clinical trials – studies that evaluate new therapies for head and neck cancers with an emphasis on approaches to improving the chances of long term remission in patients with incurable cancer using immunotherapy. He has also served the national study chair for clinical trials that give patients access to new medications and that provide new approaches of administering existing medications to improve their efficacy.

Algazi earned his medical degree from the David Geffen School of Medicine at UCLA and completed a residency in internal medicine at Ronald Reagan UCLA Medical Center. He completed a fellowship in hematology-oncology at UCSF.

Algazi is a member of the American Society of Clinical Oncology, Society for Immunotherapy for Cancer and American Association for Cancer Research.

To reach Dr. Alain Algazi, please contact the head and neck medical oncology practice at (415) 353-9900.

  • Education

    UCLA School of Medicine, 2004

  • Residencies

    UCLA Medical Center, Internal Medicine, 2007

  • Fellowships

    UCSF, Hematology-Oncology, 2010

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

  • Academic Title

    Associate Professor

There is a cure for every cancer. Our job is to find it.

Conditions I specialize in

Where I see patients (1)

    My reviews

    4.9

    Overall Experience
    172 Ratings
    About our process
    Feb 26, 2023
    Always excellent experience
    Feb 25, 2023
    Dr. Algazi is a great communicator and listener and a caring doctor.
    Jan 24, 2023
    Awesome UCSF Head and Neck Team
    Dec 26, 2022
    Always a blessing to meet with Dr Algazi
    Nov 20, 2022
    Dr Algazi is fantastic
    Sep 28, 2022
    Dr Algazi is excellent at communication and giving me hope and confidence in this process
    Sep 22, 2022
    Always so attentive and collaborative in my care
    Sep 05, 2022
    I only wish there were an 'excellent' choice.
    Aug 25, 2022
    My impressions of care team is above and beyond expectations.
    Aug 09, 2022
    I can't emphasize enough how much I appreciate the communication with this organization. You are truly to be commended.
    Jul 14, 2022
    Excellent knowledge answered all questions in detail a good listener willing to provide additional information
    Jun 04, 2022
    Dr. Algazi is second to none. He has a very calming bedside manner. He knows his stuff!! I am lucky to have him.
    Mar 20, 2022
    Covered all bases.
    Mar 19, 2022
    I was impressed by Dr Algazi's understanding of my case and his excellent knowledge of these types of cancer. His discussion of immunotherapy was especially helpful for me.
    Mar 17, 2022
    Dr Algazi is an excellent Doctor.
    Feb 26, 2022
    Excellent
    Sep 11, 2021
    Thank you Dr. Algazi
    Jul 19, 2021
    I have seen this doctor for more than 8 years as a cancer patient! So I have nothing to complain about. He has given me outstanding care.
    Jul 15, 2021
    Very satisfied care services

    Selected research

    See all research
    Decorative Caduceus

    Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

    Intratumoral CD3+ T-cells will be identified by immunohistochemistry in pre- and post-treatment tumor specimens. The analysis population for the primary outcome will be all patients who received at least 2 weeks of neoadjuvant the...

    Recruiting

    Decorative Caduceus

    Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients Wit...

    For patients who do not have a tumor recurrence or death, DFS will be censored on the date of last disease assessment.

    Recruiting

    Decorative Caduceus

    A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or M...

    Treatment emergent and treatment related adverse events (assessed by CTCAE v5.0), serious adverse events (SAEs), adverse events leading to treatment discontinuation, deaths

    Recruiting

    Decorative Caduceus

    Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants...

    The occurrence of the following toxicities, if assessed by the investigator to be possibly, probably, or definitely related to study treatment administration: Grade 4 nonhematologic toxicity (not laboratory) Grade 4 hematologic ...

    Recruiting

    Decorative Caduceus

    Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma ...

    TEAE's are defined as Adverse Events (AEs) with onset after date-time of first dose, or medical conditions present prior to the start of IMP but increased in severity or relationship after date-time of first dose of IMP.

    Recruiting

    Contact me

    Providers on my team

    Share